SAG
RLAY icon

SageView Advisory Group’s Relay Therapeutics RLAY Stock Holding History

SageView Advisory Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40
Closed -$339 – 2031
2025
Q4 		$339 Buy
+40
New +$285 ﹤0.01% 2473

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

SageView Advisory Group's RLAY Position: Q1 2026 in Review

SageView Advisory Group sold out of Relay Therapeutics (RLAY) in Q1 2026, closing a stake of 40 shares — an estimated $339 sold.

SageView Advisory Group first reported a position in RLAY in Q4 2025 and held it in 1 quarter. The position peaked at $339 in Q4 2025. 244 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • SageView Advisory Group reported no remaining Relay Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 40 Relay Therapeutics shares in Q1 2026, an estimated $339.
  • SageView Advisory Group first reported a position in Relay Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Relay Therapeutics position peaked at $339 in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.